Exagen XGN 深 滬
已收盤 02-06 16:00:00 美东时间
3.51
+0.150
+4.46%
華盛通- 最 高3.635
- 今 開3.42
- 成交量 58.18万股
- 最 低 3.37
- 昨 收 3.36
- 總市值 7954.75万
- 52周最高 12.23
- 市盈率 靜 --
- 換手率 2.57%
- 52周最低 2.6701
- 委 比 68.37%
- 總股本 2266.31万
- 歷史最高 29.858
- 量 比 0.72
- 振 幅 7.89%
- 歷史最低 1.3003
- 每 手 1
- 風險率 2.48%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 苹果、SanDisk、西部数据、卡特彼勒、德克斯户外、霍尼韦尔、西南航空、万事达等获多家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Praxis Precision Medicine"买入"评级，目标价从340美元升至1245美元；HC Wainwright & Co.：维持Perspective Therapeutics"买入"评级，目标价从10美元升至12美元
02-02 14:15
B. Riley Securities Reiterates Buy on Exagen, Lowers Price Target to $8
B. Riley Securities analyst Anderson Schock reiterates Exagen (NASDAQ:XGN) with a Buy and lowers the price target from $18 to $8.
01-30 21:52
Exagen Inc. Announces Select Preliminary 2025 Financial Results
Exagen Inc. reported preliminary 2025 financial results, highlighting record full-year revenue of $66M-$67M, up 19%-20% YoY, driven by increased AVISE CTD volumes and higher average selling prices (ASP). The company also noted a 11% rise in test volumes and a $10M increase in cash reserves, reflecting strong commercial and operational execution. CEO John Aballi emphasized continued progress in innovation and profitability, despite challenges in t...
01-11 20:00
Exagen Inc. to Participate in Fourth Quarter Investor Conferences
Exagen Inc. (Nasdaq: XGN), a leading autoimmune diagnostics provider, announced that its management will participate in two upcoming investor conferences: the 16th Annual Craig-Hallum Alpha Select Conference on November 18, 2025, and the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 20, 2025. Exagen is committed to improving autoimmune disease management through innovative testing solutions, particularly i...
2025-11-11 14:00
美股大行评级 | 花旗上调英伟达目标价从210美元升至220美元；DraftKings、DoubleVerify遭多家大行下调目标价
今日重点评级关注：Guggenheim：维持InflaRx"买入"评级，目标价从10美元升至22美元；巴克莱：维持Tandem糖尿病护理"超配"评级，目标价从51美元升至55美元
2025-11-11 10:49
美股大行评级 | 最高325美元！10家机构集体上调AMD目标价；Pinterest遭14家大行下调目标价；大行对优步目标价分歧大，5家下调5家上调
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从3美元升至9美元；HC Wainwright & Co.：上调CervoMed评级至"买入"，目标价从11美元升至25美元
2025-11-06 09:55
B. Riley Securities Reiterates Buy on Exagen, Raises Price Target to $18
B. Riley Securities analyst Anderson Schock reiterates Exagen (NASDAQ:XGN) with a Buy and raises the price target from $15 to $18.
2025-11-06 01:26
Exagen’s Earnings Call: Growth Amid Financial Hurdles
Exagen (($XGN)) has held its Q3 earnings call. Read on for the main highlights ...
2025-11-05 09:06
Exagen Affirms FY2025 Sales Guidance of $65.000M-$70.000M vs $67.487M Est
Exagen (NASDAQ:XGN) affirms FY2025 sales outlook from $65.000 million-$70.000 million to $65.000 million-$70.000 million vs $67.487 million estimate.
2025-11-04 21:02
